Clinical Trials Browser

Approved for marketing × Ovarian Neoplasms × Clear all

NCT03079687 2017-10-25

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Approved for marketing

Carcinoma, Ovarian Epithelial, Neoplasms, Ovarian Diseases, Ovarian Neoplasms

NCT03025867 2017-04-17

Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer

Approved for marketing

Ovarian Neoplasms